CHATEAU Registry: Clinical Outcomes After Transcatheter Aortic Valve Replacement (CHATEAU)
Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement: The Collaborative Hexagon-Asian Transcatheter Aortic Valve Replacement Union (CHATEAU) Registry
研究概览
详细说明
The CHATEAU Registry is an international, multicenter, observational registry of patients undergoing transcatheter aortic valve replacement. This study will retrospectively analyze consecutive 4,000 patients treated with TAVR at participating centers from January 1, 2021 to December 31, 2025. Follow-up clinical outcomes will be assessed through December 31, 2027.
Eligible patients are adults who underwent TAVR for aortic valve disease. Data will be collected from existing medical records, including baseline demographics, comorbidities, laboratory findings, pre-procedural imaging data, procedural details, device information, post-procedural echocardiographic findings, discharge medications, and clinical follow-up outcomes.
The study aims to evaluate the association between patient-, anatomy-, device-, and procedure-related factors and subsequent clinical outcomes and valve performance. Outcomes of interest may include all-cause death, cardiovascular death, stroke, myocardial infarction, heart failure hospitalization, pacemaker implantation, valve hemodynamic deterioration, aortic valve reintervention, paravalvular regurgitation, and other TAVR-related clinical events.
Because this is a retrospective observational study, all treatment decisions were made according to routine clinical practice at each participating institution. The study does not involve randomization, assignment of treatment, additional procedures, or additional patient visits. All data will be handled in accordance with applicable institutional review board requirements and privacy regulations.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Osung Kwon, MD. PhD
- 电话号码:+821037085673
- 邮箱:oscaesar@gmail.com
学习地点
-
-
-
Seoul、韩国、03312
- 招聘中
- The Catholic University of Korea, Eunpyeong St. Mary's Hospital
-
接触:
- Osung Kwon, MD, PhD
- 电话号码:+821037085673
- 邮箱:oscaesar@gmail.com
-
接触:
-
首席研究员:
- Osung Kwon, MD, PhD
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Adults (≥18 years of age).
- Patients who underwent transcatheter aortic valve replacement (TAVR) for severe native aortic valve disease at participating centers.
- TAVR performed between January 1, 2021 and December 31, 2025.
- Availability of baseline procedural and follow-up clinical data in the institutional registry or medical records.
Exclusion Criteria:
- Patients with insufficient clinical or procedural data for outcome assessment.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
CHATEAU Registry Cohort
Consecutive adult patients with severe aortic valve disease who underwent transcatheter aortic valve replacement (TAVR) between January 1, 2021 and December 31, 2025 at participating centers in the CHATEAU Registry.
Clinical, imaging, procedural, and follow-up data are collected retrospectively from routine clinical practice.
|
Transcatheter aortic valve replacement (TAVR) performed according to routine clinical practice using commercially available transcatheter heart valves and standard procedural techniques at participating centers.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
All-Cause Mortality
大体时间:From the index TAVR procedure through December 31, 2027 (up to approximately 6 years)
|
Death from any cause occurring after transcatheter aortic valve replacement (TAVR) during follow-up.
|
From the index TAVR procedure through December 31, 2027 (up to approximately 6 years)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Cardiovascular Mortality Stroke Heart Failure Hospitalization Myocardial Infarction Aortic Valve Reintervention Valve Hemodynamic Deterioration Prosthetic Valve Endocarditis/thrombosis Permanent pace maker insertion Major Bleeding
大体时间:From the index TAVR procedure through December 31, 2027 (up to approximately 6 years)
|
Outcome events will be assessed during follow-up using routinely collected clinical and imaging data.
Clinical events will be defined according to the Valve Academic Research Consortium-3 (VARC-3) criteria, where applicable, and adjudicated according to each participating center's standard clinical practice.
|
From the index TAVR procedure through December 31, 2027 (up to approximately 6 years)
|
合作者和调查者
调查人员
- 首席研究员:Osung Kwon, MD, PhD、The Catholic University of Korea Eunpyeong St. Mary's Hospital
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CHATEAU-REG-001
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.